Ephedrine comment period extended to Sept. 27.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE COMMENT PERIOD EXTENDED UNTIL SEPT. 27, FDA announced in an Aug. 29 Federal Register notice. The agency is giving industry more time to respond to its July 27 notice of proposed rulemaking to amend the monograph for over-the-counter bronchodilator drug products. The amendment would ban ephedrine's use in over-the-counter drugs due to its role as a precursor in the manufacture of controlled substances such as methamphetamine and methcathinone ("The Tan Sheet" July 31, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning